Shelly Gray editorial in The BMJ underscores importance of avoiding long-term use of anticholinergic drugs in older adults
UWSOP Plein Center for Geriatric Pharmacy Director Shelly Gray authored an editorial in support of new research about potential dangers of anticholinergic drugs for that help to control involuntary muscle movements for conditions such as epilepsy and Parkinson’s disease. The UK study, “Anticholinergic drugs and risk of dementia: case-control study,” published by The BMJ today, found these drugs are associated with an increased risk of dementia.
The study is the largest of its kind to date and the findings prompt the researchers to say that clinicians should avoid long term prescribing of some anticholinergics to patients aged 45 and over.
“This research “raises important issues about the best way to summarize anticholinergic burden for future research… Specifically, for most highly anticholinergic drugs, non-pharmacological and pharmacological alternatives are available and should be considered.” – UW Professor and Director Shelly Gray and Professor Joseph Hanlon at the University of Pittsburgh, in their editorial, “Anticholinergic drugs and dementia in older adults”
In the meantime, Gray and Hanlon agree that anticholinergics in general should be avoided in older adults.
Anticholinergic drugs block chemical signals to the brain that control muscle movements. They are often used for conditions linked to involuntary muscle movements, such as urinary incontinence, epilepsy and Parkinson’s disease, as well as for depression, chronic lung disease (COPD) and asthma.
Several studies have reported associations between use of anticholinergics and future cognitive decline and dementia, but it is not clear whether this is due to the drugs themselves or the underlying conditions for which they were prescribed.
So a research team led by Kathryn Richardson at the University of East Anglia, set out to estimate the association between duration and level of exposure to different classes of anticholinergic drugs and subsequent dementia.
They analyzed data from the UK’s Clinical Practice Research Database for 40,770 patients aged 65 to 99 years who were diagnosed with dementia between April 2006 and July 2015. Each case patient was matched to up to seven control patients of similar age and sex, but without dementia.
Drugs were scored according to their anticholinergic activity using the Anticholinergic Cognitive Burden (ACB) scale. An ACB score of 1 was classed as possibly anticholinergic, while a score of 2 or 3 was definitely anticholinergic.
Daily doses of each drug were then compared for both cases and controls over an exposure period of 4 to 20 years before a diagnosis of dementia.
A total of 14,453 (35%) cases and 86,403 (30%) controls were prescribed at least one anticholinergic drug with an ACB score of 3 during this period.
After taking account of potentially influential factors, the researchers found that definite anticholinergic antidepressants, anti-Parkinson drugs, and drugs to treat urinary incontinence (ABC score of 3) were linked to increased dementia risk up to 20 years after exposure.
However, no increased risk was found for drugs with possible anticholinergic activity (ACB score of 1) – and for anticholinergic gastrointestinal or respiratory drugs (ACB score of 3).
Other antidepressants (mainly selective serotonin reuptake inhibitors) with an ACB score of 1 were linked to dementia, but only close to the time of prescription, which the researchers say is unlikely to represent a direct (causal) link.
This is an observational study, so no firm conclusions can be drawn about cause and effect, and the authors outline some limitations, such as possible misclassification of dementia cases and a lack of information on depression severity. Nevertheless, the study was large and was able to account for several potentially influential factors.